LRMR
Larimar Therapeutics, Inc.
$4.28
+0.15 (+3.63%)
At close · Jul 10
Market Cap
$444.62M
Shares
103,882,937
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.28
Open$4.12
Day$3.85–4.32
52W$2.72–6.42
Avg vol 30d2.6M
Short int12.2M · 11.7% float · 3.2d
Short vol38%
Last earningsMay 15, 2023
DataJan 2020–Jul 2026
Filing10-Q · May 14
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+8%
above
Price vs 50-day avg
+19%
above
RSI (14)
68
neutral
MACD trend
Positive
52-week position
42%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+24%
trailing
6-month return
+31%
trailing
YTD return
+12%
this year
Relative strength
+22%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
3 of 161 funds reported for Jun 30 · net +395.9K sh shares · +1 new
Insider flow
Accumulating
Net +$166.9K over 90 days · 0% sells
Short interest
Rising
11.74% of float · ▲ +15.7% MoM · 3.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
161 holders — near 3-yr high, broad support
Squeeze score
77
high risk · 0–100
Fundamentals
EPS growth
−57%
Y/Y
Free cash flow
$-113.3M
Balance sheet
$70.9M
net cash
Quant / Vol
risk profile
Volatility
111%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
7.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+8%
Bullish
Price vs 50-day avg
+19%
Bullish
RSI (14)
68
Neutral
MACD trend
Positive
Bullish
52-week position
42%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
3 of 161 funds reported for Jun 30 · net +395.9K sh shares · +1 new
Insider flow
Accumulating
Net +$166.9K over 90 days · 0% sells
Short interest
Rising
11.74% of float · ▲ +15.7% MoM · 3.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
161 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $3
Now $4 · 42%
52-wk high $6
vs 200-day avg +8%
vs 50-day avg +19%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LRMR
this stock
Larimar Therapeutics, Inc.
|
$444.62M | +12.3% | — | — | 11.7% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LRMR | +31.3% | +24.4% | +31.3% | +40.3% | +12.3% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | +29.9% | +20.4% | +22.2% | +39.2% | +1.6% |